Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study - Summary - MDSpire

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • By

  • Carlyn Rose Tan

  • Sireesha Asoori

  • Chiung-Yu Huang

  • Larissa Brunaldi

  • Rakesh Popat

  • Efstathios Kastritis

  • Joaquin Martinez-Lopez

  • Radhika Bansal

  • Andre De Menezes Silva Corraes

  • Saurabh Chhabra

  • Ricardo Parrondo

  • Sikander Ailawadhi

  • Despina Fotiou

  • Meletios A. Dimopoulos

  • Kwee Yong

  • Catriona Mactier

  • Chris Lau

  • Magdalena Corona

  • Adolfo Jesús Sáez Marin

  • Hira Mian

  • Brian GM. Durie

  • Saad Z. Usmani

  • Thomas G. Martin

  • Yi Lin

  • April 3, 2025

  • 0 min

Share

Objective:

To evaluate the real-world safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM) treated outside of clinical trials, highlighting the importance of understanding outcomes in routine clinical practice.

Key Findings:
  • Overall response rate (ORR) was 67%, with 34% achieving very good partial response (VGPR) and 21% achieving complete response (CR), indicating significant efficacy.
  • 72.1% of patients experienced cytokine release syndrome (CRS), primarily grade ≤2, with no treatment discontinuations, highlighting manageable safety.
  • Infections occurred in 80% of patients, with 55.2% experiencing grade 3/4 infections, underscoring the need for vigilant monitoring.
Interpretation:

Teclistamab demonstrates promising efficacy in a real-world setting for heavily pretreated RRMM patients, although safety concerns, particularly regarding infections and CRS, remain significant and warrant careful monitoring.

Limitations:
  • The study is retrospective and may be subject to bias, potentially affecting the reliability of the findings.
  • A significant portion of patients did not meet eligibility criteria from the pivotal MajesTEC-1 study, which may limit generalizability.
Conclusion:

Teclistamab is effective in a diverse real-world population of RRMM patients, but careful monitoring for adverse events is essential, and further research is needed to validate these findings.

Original Source(s)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • by Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Efstathios Kastritis, Joaquin Martinez-Lopez, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A. Dimopoulos, Kwee Yong, Catriona Mactier, Chris Lau, Magdalena Corona, Adolfo Jesús Sáez Marin, Hira Mian, Brian GM. Durie, Saad Z. Usmani, Thomas G. Martin, Yi Lin

  • April 3, 2025

Related Content

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions